Table 5.
HPLC results for Partner medicines (PM)
| Partner Medicines | Below 85 % | Within 85–115 % | Above 115 % | Total N = 254 |
|---|---|---|---|---|
| Amodiaquinea
n (%) |
28 (25.2) | 64 (57.7) | 19 (17.1) | 111 (100.0) |
| Median (IQR) | 80.6 (72.6–82.9) | 92.7 (88.3–97.2) | 118.8 (117.2–121.4) | 92.0 (84.9–101.7) |
| Lumefantrineb
n (%) |
4 (3.0) | 120 (89.6) | 10 (7.5) | 134 (100.0) |
| Median (IQR) | 83.3 (77.4–84.4) | 99.4 (93.2–105.0) | 117.6 (116.2–118.5) | 100.3 (93.1–107.1) |
| Piperaquinec
n (%) |
0 (0.0) | 3 (33.3) | 6 (66.7) | 9 (100.0) |
| Median (IQR) | 0 | 112.1 (111.5–114.7) | 121.1 (117.5–123.8) | 117.5 (114.7–121.7) |
| Combined n (%) |
32 (12.6) | 187 (73.6) | 35 (13.8) | 254 (100.0) |
| Median (IQR) | 81.4 (72.8–83.0) | 96.6 (91.6–103.4) | 118.7 (117.2–120.7) | 96.8 (88.9–108.4) |
Note: a, b, cwere derived from Artesunate Amodiaquine. Artemether Lumefantrine and Dihydroartemisinin Piperaquine respectively